Patents

Fuisz Pharma Patents New Tablet, Caplet Shapes

The new shapes are designed to promote more rapid, reliable esophageal transit of oral medications.

Fuisz Pharma LLC announced today that it has received a notice of allowance from the United States Patent and Trademark Office in connection with its utility patent application entitled "Solid Dosage Form That Promotes Reliable Oral, Esophageal and GI Transit" (US 20120141545).  The allowed claims cover Fuisz Pharma's new tablet and caplet designs for improved transit, including the tablet that Fuisz Pharma calls the "Saturn".

No votes yet

Medgenics Granted Patent for Sustained Delivery of Anemia Treatment

The Biopump is intended to provide safe, sustained delivery of erythropoietin for anemia patients.

Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the “Company”), the developer of BiopumpTM a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced a patent granted by the U.S. Patent and Trademark Office (USPTO) protecting the use of Medgenics’ EPODURE Biopump technology for delivery of erythropoietin (EPO). Medgenics is developing EPODURE to address the need for safer, sustained treatment of anemia.

No votes yet

AcelRx Pharmaceuticals Receives U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms

The two new patents cover the company's family of sufentanil NanoTab pain products.

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that the U.S.

No votes yet

Patent Expirations Put More Than $290 Billion in Prescription Drug Sales at Risk

According to a report from EvaluatePharma, prescription drug sales are at risk, and spending on research is on the rise.

EvaluatePharma, the premier provider of pharmaceutical and biotech analysis including consensus forecasts, today released its World Preview 2018 report, providing an in-depth look at how the patent cliff will reshape the drug industry over the next six years — with valuable insight into which companies and products will come out as winners.

No votes yet

Auxilium Pharmaceuticals, FCB I LLC Sue Watson for Infringement of Testim Patents

The pharma firms allege that Watson is violating numerous patents with its proposed generic version of the testosterone gel.

Auxilium Pharmaceuticals, Inc. and FCB I LLC announced today that they filed a lawsuit against Watson Laboratories, Inc.; Watson Pharmaceuticals, Inc.; and Watson Pharma, Inc. (collectively, "Watson") for infringement of FCB's ten patents listed in the U.S. Food and Drug Administration's ("FDA's") Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the "Orange Book") as covering Testim 1% testosterone gel.  The lawsuit was filed in the United States District Court for the District of New Jersey on May 23, 2012.

No votes yet
Syndicate content